An update on inhaled antibiotherapy in Pseudomonas aeruginosa respiratory tract infections;Actualité de l'antibiothérapie inhalée dans les infections respiratoires à Pseudomonas aeruginosa

Medecine et Maladies Infectieuses

Volumn 32, Issue 9, 2002, Pages 460-467

  Aubron, C ^a   Rapp, C ^b   Parienti, J J ^c   Patey, O ^a  

^a Centre Hospitalier Intercommunal de Villeneuve Saint Georges   (France)

^b SERVICE D ENDOCRINOLOGIE   (France)

^c CAEN UNIVERSITY HOSPITAL   (France)

Author keywords

Cystic fibrosis; Inhaled antibiotic; Nosocomial pneumonia; Pseudomonas aeruginosa; Respiratory infection

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; GENTAMICIN; IMIPENEM; NEOMYCIN; TICARCILLIN; TOBRAMYCIN; TOBRAMYCIN SULFATE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL COLONIZATION; BACTERIAL PNEUMONIA; BLOOD TOXICITY; COST OF ILLNESS; CYSTIC FIBROSIS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; HOSPITAL INFECTION; HUMAN; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; PROGNOSIS; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; REVIEW;

EID: 0036751759     PISSN: 0399077X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0399-077X(02)00413-4     Document Type: Review

References (38)

1. er mars 2000. Antibiotiques 2001;3:50-68.
2. Le Bourgeois M, Bingen E. Aspects microbiologiques et stratégie thérapeutique dans la mucoviscidose. La lettre de l'infectiologue 2001;XVI-4:101-7.
3. Soler C, Gérôme P, Gidenne S, Hernandez E, Ramisse F, Ramirez J, et al. Alginate du Pseudomonas aeruginosa au cours de la mucoviscidose. Méd Thér 2001;7-3:240-7.
4. Pollack M. Pseudomonas aeruginosa. In: Mandell GL, Bennett JE, Dolin R, editors. Principles and practice of infectious diseases 4. 1995. p. 1980-2003 (chap197).
5. Jehl F, Chomarat M, Weber M, Gerard A. De l'antibiogramme à la prescription ed Biomérieux, 2000 p. 47.
6. Di Sant'agnese PEA, Andersen D. Celiac syndrom. Chemotherapy in infections of the respiratory tract associated with cystic fibrosis of the pancreas: observation with penicillin and drugs of the sulfonamide group, with special reference to penicillin aerosol. Am J Dis Child 1946;72:17-61.
7. Littlewood JM, Miller MG, Ghoneim AT, Ramsden CH. Nebulised colomycin for early pseudomonas colonisation in cystic fibrosis. Lancet 1985;1:865.
8. Hodson ME, Penketh ARL, Batten JC. Aerosol carbenicillin and gentamycin treatement of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Lancet 1981;ii:1137-9.
9. Jenkins SG, Kelly WC, Mason WG, et al. Aerosolized amikacin administration to cystic fibrosis patients chronically infected with Pseudomonas aeruginosa. 26th Meeting of the cystic fibrosis Foundation, Anaheim, California. 16-19 May 1985 (Abstract).
10. Faurisson F, Brun-Pascaud M. Une autre voie d'administration des aminosides: les aérosols. Comment définir le rythme optimal d'administration des aminoglycosides. Paris: Maloine; 1988. p. 53-62.
11. Le Conte P, Potel G, Peltier P, Horeau D, Caillon J, Juvin ME, et al. Lung distribution and Pharmacokinetics of aerosolized tobramycin. Am Rev Respir Dis 1993;147:1279-82.
12. Sermet-Gaudelus I, Silly C, Maout F, Monnier A, Willemot JM, Lenoir G. Aérosols d'antibiotiques et mucoviscidose. In: Derelle J, Hubert D, Scheid P, editors. La mucoviscidose de l'enfant à l'adulte. Paris: John Libbey Eurotext; 1998. p. 223-42.
13. Kucers A, Crowe M, Grayson ML, Hoy JF. Polymyxins. The use of antibiotics a clinical review of antibacterial, antifungal and antiviral drugs. Oxford: Butterworth Heinemann; 1997. p. 667-75.
14. Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamycin in cystic fibrosism. Am Rev Resp Dis 1997;136:1445-9.
15. Gilligan P. Microbiology of airway disease in patients with cystic fibrosis. Clin Microbiol Rev 1991;4:31-51.
16. Cystic fibrosis foundation. Cystic fibrosis foundation patient registry 1997 Annual data report. Bethesda, MD, USA. Cystic fibrosis foundation, 1998.
17. Frederiksen B, Koch C, Hoiby N. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in patients with cystic fibrosis. Pediatr Pulmonol 1997;23:330-5.
18. Valerius NH, Koch C, Hoiby N. Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatement. Lancet 1991;338:725-6.
19. Burns JL, Van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999;179:1190-6.
20. Vazquez C, Municio M, Corera M, et al. Early treatment of Pseudomonas aeruginosa colonization in cystic fibrosis. Acta Paediatr 1993;82:308-9.
21. Sermet-Gaudelus I, Silly C, Sorin M, Maout F, Sebai L, Lenoir G. Interest of inhaled antibiotics for treatment of first colonization by Pseudomonas aeruginosa in cystic fibrosis. Israel J Med Sci 1995;31:S170.
22. Schaad UB, Wedgwood-krucko J, Suter S, Kraemer R. Efficacy of inhaled amikacin as adjunct to intravenous combination therapy (ceftazidime and amikacin) in cystic fibrosis. J Pediatr 1987;111:599-605.
23. Mukhopadhyay S, Singh S, Cater JI, Ogston S, Franklin M, Olver RE. Nebulised antipseudomonal antibiotic therapy in cystic fibrosis: a metaanalysis of benefits and risks. Thorax 1996;51:364-8.
24. Ramsey B, Dorkin HL, Eisenberg JED, Gibson RL, Harwood IR, Kravitz RM, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328:1740-6.
25. Ramsey BW, Pepe MS, Quan JM, Otto KL, Montgomery AB, Williams-Warren J, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med 1999;340:23-30.
26. Tamm M, Eich CH, Frei R, Gilgen S, Breitenbücher A, Mordasini C. Inhalatives colistin bei zystischer fibrose. Schweiz Med Wochenschr 2000;130:1366-72.
27. Bauldoff GS, Nunley DR, Manzetti JD, Dauber JH, Keenan RJ. Use of aerosolized colisfin sodium in cystic fibrosis patients awaiting lung transplantation. Transplantation 1997;64:748-52.
28. National Nosocomial Infections Surveillance (NNIS) System. National Nosocomial Infections Surveillance report, data summary from 1986 October-April 1996, issued May 1996. Am J Infect Control 1996;24:380-8.
29. Pennington JE. Nosocomial respiratory infections. In: Mandel GL, Douglas RG, Bennett's JE, editors. Principles and practice of infectious diseases, II. New York: Churchill Livingstone; 1990. p. 2599-607.
30. Hamer DH. Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin. Am J Respir Crit Care Med 2000;162:328-30.
31. Le Conte Ph, Potel G, Clémenti E, Legras A, Villers D, Bironneau E, et al. Administration d'aérosols de tobramycine chez des patients ayant une pneumopathie nosocomiale: étude préliminaire. Presse med 2000;29:76-8.
32. Barker AF, Couch L, Fiel SB, Gotfried M, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Resp Crit Care Med 2000;162:481-5.
33. Zylberger H, Vargaftig J, Barbieux C, Pertuiset N, Rothschild C, Viard JP. Prolonged efficiency of secondary prophylaxis with colistin aerosols for respiratory infection due to Pseudomonas aeruginosa in patients infected with human immunodeficiency virus. CID 1996;23:641-3.
34. Smith AL, Ramsey BW, Hedges DL, et al. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis. Ped Pulmonol 1989;7:265-71.
35. Maddison J, Dood M, Webb AK. Nebulised colistin causes chest tightness in adults with cystic fibrosis. Respir Med 1994;88:145-7.
36. Dodd ME, Abbott J, Maddison J, Moorcroft AJ, Webb AK. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis. Thorax 1997;52:656-8.
37. Maclusky I, Gold R, Corey M, et al. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989;7:42-8.
38. Tamm M, Eich C, Frei R, Gilgen S, Breitenbücher A. Inhalatives colistin bei zystischer fibrose. Schweiz Med Wochenschr 2000;130:1366-72.